Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report) today and set a price target of $9.00. The company’s shares opened today at $0.86.
According to TipRanks, Goldstein is an analyst with an average return of -4.0% and a 34.07% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Arcus Biosciences, and Verastem.
Currently, the analyst consensus on Adaptimmune Therapeutics is a Moderate Buy with an average price target of $9.50.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $2.65 and a one-year low of $0.85. Currently, Adaptimmune Therapeutics has an average volume of 892.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Read More on ADAP:
